• 1
    Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping ‘plague’. Annu Rev Med 2002; 53: 7588.
  • 2
    Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 48894.
  • 3
    Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 40439.
  • 4
    Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 4339.
  • 5
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 176572.
  • 6
    Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, Ferrari S, Konetschny C, Antoine G, Rieger M, Scheiflinger F. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107: 11825.
  • 7
    Studt JD, Hovinga JAK, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lammle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 5424.
  • 8
    Zhou Z, Han H, Cruz MA, Lopez JA, Dong JF, Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009; 101: 10707.
  • 9
    Larkin D, De Laat B, Jenkins V, Bunn J, Craig AG, Terraube V, Preston RJS, Donkor C, Grau GE, Van Mourik JA, O’Donnell JS. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog 2009; 5: e1000349.
  • 10
    Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub) endothelial VWF from cleavage by ADAMTS13. Blood 2006; 107: 95564.
  • 11
    Cao WJ, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA 2008; 105: 741621.
  • 12
    Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 52834.
  • 13
    Crawley JTB, Lam JK, Rance JB, Mollica LR, O’Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 108593.
  • 14
    Lam JK, Chion CKNK, Zanardelli S, Lane DA, Crawley JTB. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost 2007; 5: 101018.
  • 15
    Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 1118.
  • 16
    Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF – a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 13869.
  • 17
    Wiman B. Affinity-chromatographic purification of human alpha-2-antiplasmin. Biochem J 1980; 191: 22932.
  • 18
    Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino-acids 1 to 263 of tissue-type plasminogen-activator and amino-acids 144 to 411 of urokinase-type plasminogen-activator. J Biol Chem 1987; 262: 1085562.
  • 19
    Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 53440.
  • 20
    Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281: 8507.
  • 21
    Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 158594.
  • 22
    Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097103.
  • 23
    Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 32413.
  • 24
    Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 26774.
  • 25
    Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 119027.
  • 26
    Holvoet P, Deboer A, Verstreken M, Collen D. An enzyme-linked-immunosorbent-assay (ELISA) for the measurement of plasmin-alpha-2–antiplasmin complex in human-plasma – application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986; 56: 1247.
  • 27
    Holmes WE, Lijnen HR, Collen D. Characterization of recombinant human alpha-2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry 1987; 26: 513340.
  • 28
    Lijnen HR, Bloemmen F, Vereecken A, Collen D. Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples. Thromb Res 2001; 102: 539.
  • 29
    Holvoet P, Lijnen HR, Collen D. A monoclonal-antibody specific for Lys-plasminogen – application to the study of the activation pathways of plasminogen in vivo. J Biol Chem 1985; 260: 210611.
  • 30
    Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha(2)-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93: 227481.
  • 31
    Feys HB, Pareyn I, Vancraenenbroeck R, De Maeyer M, Deckmyn H, Van Geet C, Vanhoorelbeke K. Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura. Blood 2009; 114: 474952.
  • 32
    Ogawa T, Verhamme IM, Sun MF, Bock PE, Gailani D. Exosite-mediated substrate recognition of factor IX by factor XIa – the factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem 2005; 280: 2352330.
  • 33
    Hayashi J, Salomon DR, Hugli TE. Elevated kallikrein activity in plasma from stable liver transplant recipients. Int Immunopharmacol 2002; 2: 166780.
  • 34
    Brinkmann T, Schnierer S, Tschesche H. Recombinant aprotinin homolog with new inhibitory specificity for cathepsin-G. Eur J Biochem 1991; 202: 959.
  • 35
    Edy J, Decock F, Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human-plasma. Thromb Res 1976; 8: 51318.
  • 36
    Andersen JC, Switzer MEP, McKee PA. Support of ristocetin-induced platelet-aggregation by procoagulant-inactive and plasmin-cleaved forms of human factor-VIII-von Willebrand factor. Blood 1980; 55: 1018.
  • 37
    Berkowitz SD, Dent J, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS. Epitope mapping of the von Willebrand-factor subunit distinguishes fragments present in normal and type-IIa von Willebrand disease from those generated by plasmin. J Clin Invest 1987; 79: 52431.
  • 38
    Maino A, Garagiola I, Artoni A, Al Humood S, Peyvandi F. A novel mutation of alpha 2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia 2008; 14: 1669.
  • 39
    Zheng XL, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 3013641.
  • 40
    Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102: 32327.
  • 41
    Carpenter SL, Mathew P. Alpha(2)-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008; 14: 12504.
  • 42
    Taberner DA, Ralston AJ, Ackrill P. Acquired alpha-2 anti-plasmin deficiency in glomerular proteinuria. BMJ 1981; 282: 1121.
  • 43
    Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E. Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol 2008; 26: 2416.
  • 44
    Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med 1985; 79: 3946.
  • 45
    Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 813.
  • 46
    Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003; 120: 8214.